FDA publishes Guideline Draft on the Registration of Production Sites
Recommendation
14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In our News from 11 September 2013, we reported about FDA's initiative to identify production sites according to a uniform system. The identification should be enabled thanks to a D-U-N-S- (Data Universal Numbering System) number (composed of 9 figures) allocated by the company Dun & Bradstreet.
The topic seems to be crucial for the FDA as it has now released the draft of a "Guidance for Industry" entitled: "Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration". The draft comprises 5 pages including the title page. The actual content (introduction, background, and description of the UFI system) is laid down in one and a half pages. In the end, the only statement of the FDA is that the DUNS number is suitable to the identification of sites. If an alternative identifier shall be used, the FDA should be contacted.
The draft was published on 4 September 2013 and can be commented on within 60 days.
The document can be found here.
Related GMP News
23.09.2026New Version of PDA Technical Report No. 60 on Process Validation Published
16.09.2026Equipment Design in the FDA's Focus
09.09.2026Equipment Validation: A New Term at the FDA?
02.09.2026Cloud Computing: Authorities' Expectations od Cloud Service Providers?
26.08.2026Cloud Computing: IT Infrastructure Qualification by a SAAS Provider
26.08.2026Detailed Analysis of the PIC/S Document 'Recommendations on Qualification and Validation' - Part II